Six Early-Stage Medical Innovation Projects Unveiled at China Healthcare Innovation Asset Salon – Series 2
VCBeat
Internet Medical Health Media
To accelerate the realization of value for China’s high-quality healthcare assets, the 2026 Top 100 Conference will launch a diversified range of online and offline matchmaking activities. By establishing more efficient mechanisms to facilitate in-depth communication between innovative projects and core buyers, the conference aims to drive exponential value growth for premium assets. Selected participating projects will gain end-to-end exposure and matchmaking opportunities.
Targeted Express Lane (Early March to Early April 2026, Online): Organized around three thematic tracks—Early-Stage, Growth-Stage, and Pre-IPO. Each track will feature 5–6 innovative projects, with targeted invitations extended to core buyers, including venture capital (VC) firms, state-owned capital entities, and corporate venture capital (CVC) investors, for online interaction. High-quality projects will gain direct access to the offline Premium Asset Promotion Conference, securing precise matchmaking opportunities on a broader platform.
March 19 (Thursday) 15:00 VCBeat Joins Hands with Six Projects to Launch the Second Session of the Target Direct Train [Early-Stage Special Roadshow], covering early-stage projects in sectors such as andrology devices, cell therapy, AI-enabled synthetic biology, urological laser lithotripsy, gene therapy for hereditary deafness, and AI-driven drug discovery.Guests from institutions such as Yuanhe Origin, Shangjun Investment, Qisheng Investment, Daotong Investment, and FreeS Fund were also invited to participate.
Project Overview:
Yuangang (Guangzhou) Intelligent Technology Co., Ltd. is dedicated to providing users with precise health management and auxiliary diagnostic data through intelligent wearable medical devices. Its flagship product, the “Yuangang Flexible Sensor,” utilizes cutting-edge “flexible fabric strain sensors” based on advanced material technologies, combined with artificial intelligence algorithms and a data analysis engine, to enable real-time and long-term monitoring of male erectile function. This device facilitates remote home monitoring while offering comfort, accuracy, ease of use, and affordability. The collected data can be analyzed by professional physicians to formulate personalized treatment and healthcare plans for users, representing a significant innovative breakthrough in the field of men’s medical health management.
Project Overview:
NutrigeneAI Biotech Limited (Maiyuan Chuangke (Shenzhen) Biotechnology Co., Ltd.) is a cutting-edge biotechnology company founded in Hong Kong in 2023 by Professor Wing-Tak Wong from the School of Life Sciences at The Chinese University of Hong Kong and Chief Financial Officer Gary Ng. The company’s core technologies are derived from Professor Wong’s extensive pioneering research in induced pluripotent stem cell (iPSC) and cardiovascular fields. Led by CEO Dr. Biao Wang, a recipient of the “Qiming Program” for returnees from Stanford University with profound experience in the biopharmaceutical industry (including Johnson & Johnson Pharmaceuticals and Simcere Pharmaceutical), the company focuses on developing allogeneic endothelial cell (EC) therapies. It is dedicated to overcoming ischemic vascular diseases—such as peripheral artery disease (PAD), critical limb ischemia (CLI), and diabetic foot ulcers—through cellular regenerative technologies. We have pioneered a patented platform for Type II cytokine-enhanced iPSC-derived endothelial cells (iPSC-ECs), leveraging endothelial function enhancement technology to create scalable, allogeneic, off-the-shelf products with HLA compatibility designed to minimize the risk of immune rejection. Our mission is to provide transformative limb salvage and tissue regeneration solutions for patients suffering from peripheral artery disease (PAD), critical limb ischemia (CLI), and acute ischemic stroke. We strive to build a world where no patient is left behind without options!
Project Overview:
Nanjing Fuguang Dekang Medical Technology Co., Ltd. (hereinafter referred to as “Fuguang Dekang”) is an innovative enterprise integrating research and development, manufacturing, sales, and services, specializing in high-end laser medical equipment and supporting consumables. Established in 2025 at the Nanjing Medical Device Industrial Park, Fuguang Dekang has licensed multiple laser-related invention patents from the Chinese Academy of Sciences (CAS). Its product portfolio covers high-end laser medical devices and associated consumables for urology, hepatobiliary surgery, gastroenterology, cardiovascular and cerebrovascular care, dentistry, and medical aesthetics.Adhering to a development strategy that integrates industry, academia, research, medicine, and engineering, Fuguang Dekang’s core R&D team comprises chief scientists from CAS, senior laser technology researchers, and experts in precision manufacturing. By collaborating with renowned clinical experts from domestic hospitals and aligning with national policies promoting the big health industry, the company adopts a model centered on “closely following clinical needs and leading development through technological innovation.” It strives to advance China’s high-end laser medical equipment toward greater safety and efficacy, thereby facilitating progress in clinical medical technologies into more cutting-edge fields.
Project Overview:
Terpenoids are organic compounds composed of isoprene units, with over 80,000 known structures exhibiting diverse biological activities. Widely distributed in plants, insects, and microorganisms, terpenoids serve as key components in various fragrances and pharmaceuticals. With the rapid advancement of synthetic biology, the research and development of terpenoids are increasingly becoming a significant force driving biotechnological innovation and accelerating industrial upgrading. In the production of natural terpenoid products, the industry commonly employs methods such as plant extraction, chemical synthesis, and model microbial synthesis; however, these approaches suffer from drawbacks including low compound content, unstable supply, and high energy consumption and pollution. Xi’an Zhuohong Chaoyuan has pioneered a synthetic biology-based project for the efficient, low-cost production of terpenoids. Leveraging robust engineered strains and optimized fermentation processes, the company has established “super microbial factories” characterized by ultra-high yields, ultra-high conversion rates, and environmental friendliness. Compared with traditional methods, Zhuohong Chaoyuan’s “super microbial factories” utilize innovative microbial cell factories combined with artificial intelligence and supercomputing simulation platforms to dynamically regulate and optimize metabolic pathways. This approach has overcome technical bottlenecks associated with conventional microbial synthesis, such as low productivity and toxicity limitations, successfully achieving scalable production of multiple terpenoids while ensuring product quality and cost advantages.
Project Overview:
Guangzhou YouTing Biotechnology Co., Ltd., established in October 2024, is a high-tech biotechnology company dedicated to gene therapy for hereditary hearing loss. With 18 years of development history and professional expertise in the field of auditory function testing for hearing impairment, YouTing focuses on adeno-associated virus (AAV) vector-based gene therapies for deafness, providing optimal solutions to help patients with hearing loss return to the world of sound.
Project Overview:
Molecular Potential Energy (MolPE) is dedicated to leveraging artificial intelligence to profoundly transform the biopharmaceutical R&D process, with the mission of “making drug development simpler through AI.” Its core product, the MolPE BioX Intelligent Drug Discovery Platform, employs a modular and scalable framework to achieve a fully digital closed loop of “design-experiment,” covering the entire workflow from target identification to molecular optimization. Focusing on the development of innovative anti-cancer therapeutics, the platform is user-friendly and customizable, using AI to redefine the paradigm of drug discovery.
Scan the QR code to reserve your spot for the live broadcast
For more roadshow information:
Ms. Cheng - 18325011310 (WeChat ID same as phone number)
